SCHEMBL22207151

SCHEMBL22207151

COc1ccnc(N)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.45
G6PD P11413 1/20 0.44
NOS3 P29474 3/20 0.39
NOS2 P35228 3/20 0.39
NOS1 P29475 1/20 0.39
HASPIN Q8TF76 1/20 0.38
DYRK2 Q92630 1/20 0.38
IKBKB O14920 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
MET P08581 1/20 0.36
AXL P30530 1/20 0.36
MST1R Q04912 1/20 0.36
TYRO3 Q06418 1/20 0.36
PDE5A O76074 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29637501 1.00 DYRK1A (0.45) DYRK1AG6PDNOS3NOS2NOS1
Hydrochloric Acid SCHEMBL31210746 0.98 DYRK1A (0.44) DYRK1AG6PDNOS3NOS2NOS1
SCHEMBL22224597 0.80 HPGD (0.46) NOS3NOS2IKBKBMAPK1L3MBTL1
SCHEMBL30320423 0.78 DYRK1A (0.40) DYRK1AG6PDHASPINDYRK2MAPK1
SCHEMBL29745025 0.78 NOS3 (0.52) DYRK1ANOS3NOS2NOS1IKBKB
SCHEMBL2954177 0.78 NOS3 (0.52) DYRK1ANOS3NOS2NOS1IKBKB
SCHEMBL1662248 0.78 DYRK1A (0.40) DYRK1AG6PDHASPINDYRK2MAPK1
SCHEMBL8173403 0.78 DYRK1A (0.39) DYRK1AG6PDNOS3NOS2NOS1
SCHEMBL23624007 0.77 HASPIN (0.46) DYRK1AG6PDHASPINDYRK2MAPK1
SCHEMBL22235384 0.77 NOS3 (0.41) DYRK1ANOS3NOS2NOS1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 US disclosed
CN-114423758-B Antibacterial compounds 爱尔兰詹森科学公司 2025-05-27 CN disclosed
CN-114174278-B Dihydroorotate dehydrogenase inhibitors 詹森生物科技公司 2024-08-23 CN disclosed
US-20240199611-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2024-06-20 US disclosed
EP-4028399-B1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2024-02-14 EP disclosed
EP-4308239-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2024-01-24 EP disclosed
CN-117396475-A Antibacterial compounds 爱尔兰詹森科学公司 2024-01-12 CN disclosed
EP-3908579-B1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2023-12-27 EP disclosed
EP-3956320-B1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2023-11-29 EP disclosed
US-11753393-B2 Dihydroorotate dehydrogenase inhibitors JANSSEN BIOTECH, INC. 2023-09-12 US disclosed
WO-2021048342-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2021-03-18 WO disclosed
US-20200331881-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. 2020-10-22 US disclosed
WO-2020212897-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2020-10-22 WO disclosed
US-10780092-B2 Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators MERCK SHARP & DOHME CORP. (US) 2020-09-22 US disclosed
WO-2020144638-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2020-07-16 WO disclosed
WO-2020144638-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2020-07-16 WO disclosed
US-20190307753-A1 FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME CORP. (US) 2019-10-10 US disclosed
EP-3458066-A1 FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS Merck Sharp & Dohme Corp. (US) 2019-03-27 EP disclosed
WO-2017197555-A1 FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME CORP. (US) 2017-11-23 WO disclosed
WO-2017200825-A1 FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME CORP. (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753393-B2 Dihydroorotate dehydrogenase inhibitors DHODH, DLD, DPYD DYRK1A 3294/4885G6PD 14/4885NOS3 1338/4885
US-20240199611-A1 ANTIBACTERIAL COMPOUNDS FDPS, MT-ND4, NDUFS3 DYRK1A 4544/4885G6PD 151/4885NOS3 1441/4885
US-20190307753-A1 FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS PDE2A, PDE3A, PDE5A DYRK1A 1060/4885G6PD 632/4885NOS3 301/4885
US-10780092-B2 Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators PDE2A, PDE3A, PDE5A DYRK1A 1054/4885G6PD 644/4885NOS3 293/4885
US-20200331881-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, DLD, DPYD DYRK1A 3294/4885G6PD 14/4885NOS3 1338/4885
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use SCD5, SCD, FADS2 DYRK1A 3907/4885G6PD 79/4885NOS3 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.